Compare GSK plc (GSK) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while iShares 0 3 Month Treasury Bond ETF trades at $100.55. The key difference: GSK plc pays a 3.49% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| GSK | SGOV | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $100.74 |
52-Week Low | $36.20 | $100.28 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.545, up 0.02% over 24 hours, with technical indicators showing a bullish trend from moving averages but mixed signals from oscillators. The ETF offers a low-risk cash alternative with a yield around 3.5–3.65% and minimal expense ratio of 0.09%, attracting significant investor inflows amid rate uncertainty. Recent news highlights its role in diversification and income strategies for conservative portfolios.
Outlook remains positive for SGOV as a safe-haven asset, benefiting from Federal Reserve policy speculation and demand for short-term yield. Risks include interest rate volatility and competition from similar ETFs. Wall Street sentiment is favorable, with analysts endorsing its cost efficiency and liquidity for cash management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
